Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;62(6):673-680.
doi: 10.1002/mus.27038. Epub 2020 Aug 10.

Fatigue in chronic inflammatory demyelinating polyneuropathy

Karissa L Gable  1 , Hrayr Attarian  2 , Jeffrey A Allen  2   3
Affiliations

Fatigue in chronic inflammatory demyelinating polyneuropathy

Karissa L Gable et al. Muscle Nerve. 2020 Dec.

Abstract

Introduction: In this study we aimed to better understand fatigue in chronic inflammatory demyelinating polyneuropathy (CIDP) as it relates to disease activity status.

Methods: Patients with probable or definite CIDP were stratified into active CIDP or CIDP in remission. Assessments of fatigue, physical impairment, disability, sleepiness, sleep quality, and depression were collected.

Results: Of the 85 patients included in the study, 46 (54%) had active disease, whereas 39 (46%) were in remission. Fatigue was substantial in both groups, but was more severe in the active group. Use of sedating medications was a major contributor to fatigue. Sleep quality was poor in both groups, whereas depression more commonly affected those with active CIDP. Inflammatory Neuropathy Cause and Treatment disability, poor sleep quality, and higher level of depression had the greatest effect on fatigue severity.

Discussion: Fatigue is common in CIDP regardless of the disease activity state. Minimizing sedating medications, improving sleep quality, and managing depression may improve CIDP-associated fatigue.

Keywords: autoimmune diseases, chronic inflammatory demyelinating polyneuropathy, fatigue, quality of life.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Merkies IS, Schmitz PI, Samijn JP, van der Meche FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Neurology. 1999;53:1648-1654.
    1. Drory VE, Bronipolsky T, Bluvshtein V, Catz A, Korczyn AD. Occurrence of fatigue over 20 years after recovery from Guillain-Barré syndrome. J Neurol Sci. 2012;316:72-75.
    1. Forsberg A, Press R, Holmqvist LW. Residual disability 10 years after falling ill in Guillain-Barré syndrome: a prospective follow-up study. J Neurol Sci. 2012;317:74-79.
    1. Gorson KC, van Schaik IN, Merkies IS, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst. 2010;15:326-333.
    1. Hughes RA, Gorson KC, Cros D, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2010;74:651-657.

Substances

LinkOut - more resources